Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Generic Pharmaceuticals Regulation Experts: Healthcare Consultants

March 26, 2008
Adulterated Chinese Heparin, It Happens.
By a GLG Expert Contributor
Analysis of: Heparin Find May Point to Chinese Counterfeiting (www.nytimes.com)
The FDA at the end of it's investigation finds a firm in compliance or the firm gets a form 483, the pharmaceutical version of a speeding ticket.
March 12, 2008
TEVA may compete with Pfizer for market share of Camptosar
By a GLG Expert Contributor
Analysis of: Teva Announces Approval Of Generic Camptosar(R) (www.pipelinereview.com)
The article does not tell if TEVA was the first generic to market. Certainly being generic TEVA will gain some market share from Pfizer
David Zimmerman, PharmD, President/Owner
Doctors of Pharmacy, Inc.
February 11, 2008
Fosamax generic...
Analysis of: Teva wins FDA OK to sell generic Fosamax (www.reuters.com)
It is important to understand the generic implications when it comes to drug product olacement on the formulary.
David Zimmerman, PharmD, President/Owner
Doctors of Pharmacy, Inc.
February 11, 2008
Zyprexa safety
Analysis of: FDA Advisory Committee Supports Efficacy and Safety of Zyprexa (www.fiercebiotech.com)
This article is informative because it draws conclusions about Zyprexa.
February 11, 2008
TEVA wins first generic approval of Foxamax®, expect TEVA to hold market share
By a GLG Expert Contributor
Analysis of: Teva wins FDA OK to sell generic Fosamax (www.reuters.com)
The first supplier to the market of a generic drug typically holds the market share.
February 7, 2008
There are opportunities to keep market share, and one set of words describes it "Life Cycle Management"
By a GLG Expert Contributor
Analysis of: Indication Expansion: Opportunities for successful lifecycle management (www.pipelinereview.com)
Key Implications in this brief are going to be limited as this area of "Life Cycle Management" is very broad.  Such a topic is worth hundreds of pages.
February 6, 2008
Somaxon Pharmaceuticals, Inc. will not produce a shining star when it launches SILENOR™
By a GLG Expert Contributor
Analysis of: Somaxon Pharmaceuticals Submits New Drug Application For SILENOR(TM) For The Treatment Of Insomnia (www.pipelinereview.com)
The market for sleep medications is already quite flooded.   Many of the consumers of these drugs build up a tolerance or find them less than satisfactory.  On these point the drug SILENOR™ has a chance of gaining market share.
February 6, 2008
Penwest Favicon has promise in the long term
By a GLG Expert Contributor
Analysis of: Penwest pain drug fails midstage study (www.businessweek.com)
Penwest for many years had and has close alliances with firms that have superior drug delivery capability.  This news will help the firm eventually win the day.
January 22, 2008
Wellpoint has seen the Doctor and the Prescription is set to work
By a GLG Expert Contributor
Analysis of: WellPoint patients to review doctors online (www.healthcarefinancenews.com)
Wellpoint is forging new territory rating the doctors office.
January 14, 2008
TEVA will rise above
By a GLG Expert Contributor
Analysis of: Teva falls after unit CEO departs (www.businessweek.com)
Teva has grown strong, and has lost one of its top men, yet many remain and reorganization can take place.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 Next21 to 30 of 179

Analytics


Generated at 2009-01-07T13:00:17.563